A prospective study of cangrelor P2Y12-inhibition in patients with ST-segment elevation myocardial infarction : A real world experience

Trial Profile

A prospective study of cangrelor P2Y12-inhibition in patients with ST-segment elevation myocardial infarction : A real world experience

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Cangrelor (Primary) ; Ticagrelor
  • Indications Myocardial infarction
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top